FindTrial
Sign In

Prognostic Potential of Detection of WT1-mRNA in Acute Myeloid Leukemia

Prognostic Potential of Detection of WT1-mRNA in Acute Myeloid Leukemia - Prognostic Potential of Detection of WT1-mRNA in AML

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1090220039
Enrollment
50
Registered
2010-06-10
Start date
2010-06-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia (AML)

Interventions

Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use:

Sponsors

Shuichi Miyawaki; Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital.
Lead Sponsor
Hideki AKiyama
Collaborator
Division of Hematology, Tokyo Metropolitan Komagome Hospital, Junji Tomiyama
Collaborator
Division of Hematology, Tokyo Metropolitan Bokutoh Hospital, and Yasuji Kouzai, Tokyo Metropolitan Tama Medical Center.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Untreated, de novo AML patients, who are positive for WT1-mRNA at diagnosis and achieve complete remission after initial remission-induction therapy.

Exclusion criteria

Exclusion criteria: AML patients who do not meet the above condition.

Design outcomes

Primary

MeasureTime frame
Correlation between the level of WT1-mRNA in bone marrow after achieving CR state and 1-year relapse-free survival.—

Secondary

MeasureTime frame
Correlation between characteristics of the patients and the change of WT1-mRNA level and survival.—

Countries

Japan

Contacts

Public ContactISHIYAMA, Ken

Tokyo Metropolitan Ohtsuka Hospital

ishiyama-knz@umin.ac.jp+81-3-3941-3211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026